Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2003 2
2004 2
2005 3
2006 2
2007 2
2008 2
2009 2
2013 5
2014 6
2015 10
2016 4
2017 3
2018 2
2019 6
2020 4
2021 5
2022 14
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs.
Bermingham WH, Bhogal R, Arudi Nagarajan S, Mutlu L, El-Shabrawy RM, Madhan R, Krishnaswamy UM, Murali MR, Kudagammana ST, Shrestha R, Sumantri S, Christopher DJ, Mahesh PA, Dedicoat M, Krishna MT. Bermingham WH, et al. Among authors: mutlu l. Clin Exp Allergy. 2022 Mar;52(3):375-386. doi: 10.1111/cea.14084. Epub 2022 Jan 20. Clin Exp Allergy. 2022. PMID: 34939251 Review.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH, Adjei NN, McNamara B, Mutlu L, Harold JA, Clark M, Altwerger G, Dottino PR, Huang GS, Santin AD, Azodi M, Ratner E, Schwartz PE, Andikyan V. Gelissen JH, et al. Among authors: mutlu l. Ann Surg Oncol. 2023 Sep;30(9):5597-5609. doi: 10.1245/s10434-023-13757-0. Epub 2023 Jun 26. Ann Surg Oncol. 2023. PMID: 37358686 Review.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L, Manavella DD, Bellone S, McNamara B, Harold JA, Mauricio D, Siegel ER, Buza N, Hui P, Hartwich TMP, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Altwerger G, Ratner ES, Huang GS, Clark M, Andikyan V, Azodi M, Dottino PR, Schwartz PE, Santin AD. Mutlu L, et al. Mol Cancer Ther. 2023 Dec 1;22(12):1404-1412. doi: 10.1158/1535-7163.MCT-23-0126. Mol Cancer Ther. 2023. PMID: 37676984
Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L, Harold J, Tymon-Rosario J, Santin AD. Mutlu L, et al. Expert Rev Anticancer Ther. 2022 Mar;22(3):249-258. doi: 10.1080/14737140.2022.2044311. Epub 2022 Feb 24. Expert Rev Anticancer Ther. 2022. PMID: 35176955 Review.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella DD, Demirkiran C, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Mauricio D, et al. Among authors: mutlu l. Gynecol Oncol. 2023 Mar;170:38-45. doi: 10.1016/j.ygyno.2022.12.018. Epub 2023 Jan 5. Gynecol Oncol. 2023. PMID: 36610380 Free PMC article.
Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom.
Ahuja M, Dorr A, Bode E, Boulton APR, Buckland M, Chee S, Dalley C, Denman S, Ekbote A, Elkhalifa S, El-Shanawany T, Eren E, Herwadkar A, Garcez T, Ghanta H, Grammatikos A, Grigoriadou S, Jain R, Lorenzo L, Manson A, Moon E, Murng S, Murphy A, Mutlu L, Peters N, Sooriyakumar K, Stroud C, Townsend K, Yellon RL, Yong P, Kiani-Alikhan S. Ahuja M, et al. Among authors: mutlu l. Allergy. 2023 May;78(5):1380-1383. doi: 10.1111/all.15641. Epub 2023 Jan 24. Allergy. 2023. PMID: 36609839 No abstract available.
77 results